Actelion Share Price

Stocks

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
22/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	+0.99%	-	-	0
WUXI APPTEC CO., LTD.	-0.21%	-4.43%	+44.40%	+74.13%	66.22B
ARGENX SE	-3.51%	-0.26%	+6.68%	+67.80%	55.2B
LONZA GROUP AG	+0.55%	+3.84%	+11.96%	+91.39%	52.79B
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	45.53B
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	43.94B
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	41.64B
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.87%	-7.36%	+25.80%	-2.36%	25.84B
GENMAB A/S	-0.76%	+3.16%	+35.89%	+25.86%	23.51B
Average	-1.04%	+4.07%	+50.33%	+121.64%	43.19B
Weighted average by Cap.	-0.82%	+3.72%	+49.27%	+125.98%